Novo Nordisk A/S has entered a collaboration with Korro Bio Inc of the US to develop a potentially new class of genetic medicines for cardiometabolic diseases. This includes new drugs for diabetes and obesity, medicines of which Novo already has a global market position. Announced on 16 September, the deal has a value of up to $530 million which covers upfront, development and commercial milestone payments. This is in addition to the financing of R&D for potential projects and royalties from any products that reach the market.
